These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1418025)

  • 1. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity.
    Schmitt WH; Heesen C; Csernok E; Rautmann A; Gross WL
    Arthritis Rheum; 1992 Sep; 35(9):1088-96. PubMed ID: 1418025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum markers of T cell activation in relapses of Wegener's granulomatosis.
    Stegeman CA; Tervaert JW; Huitema MG; Kallenberg CG
    Clin Exp Immunol; 1993 Mar; 91(3):415-20. PubMed ID: 8443965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers of T-cell activation in relapses of Wegener's granulomatosis.
    Stegeman CA; Tervaert JW; Huitema MG; Kallenberg CG
    Adv Exp Med Biol; 1993; 336():389-92. PubMed ID: 8296642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.
    Arranz O; Ara J; Rodríguez R; Saurina A; Mirapeix E; Darnell A
    J Nephrol; 2000; 13(1):59-64. PubMed ID: 10720216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity.
    D'Cruz D; Direskeneli H; Khamashta M; Hughes GR
    J Rheumatol; 1999 Jan; 26(1):103-9. PubMed ID: 9918249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
    Schmitt WH; Csernok E; Kobayashi S; Klinkenborg A; Reinhold-Keller E; Gross WL
    Arthritis Rheum; 1998 Mar; 41(3):445-52. PubMed ID: 9506572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
    Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
    J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis.
    Wang G; Hansen H; Tatsis E; Csernok E; Lemke H; Gross WL
    Am J Med; 1997 Jun; 102(6):517-23. PubMed ID: 9217665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential B- and T-cell activation in Wegener's granulomatosis.
    Popa ER; Stegeman CA; Bos NA; Kallenberg CG; Tervaert JW
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):885-94. PubMed ID: 10329824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients.
    Thai LH; Charles P; Resche-Rigon M; Desseaux K; Guillevin L
    Autoimmun Rev; 2014 Mar; 13(3):313-8. PubMed ID: 24225075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides.
    Schönermarck U; Csernok E; Trabandt A; Hansen H; Gross WL
    Clin Exp Rheumatol; 2000; 18(4):457-63. PubMed ID: 10949720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup.
    Stegeman CA; Tervaert JW; Huitema MG; de Jong PE; Kallenberg CG
    Arthritis Rheum; 1994 Aug; 37(8):1228-35. PubMed ID: 7519859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.
    Tomasson G; Lavalley M; Tanriverdi K; Finkielman JD; Davis JC; Hoffman GS; McCune WJ; St Clair EW; Specks U; Spiera R; Stone JH; Freedman JE; Merkel PA;
    J Rheumatol; 2011 Jun; 38(6):1048-54. PubMed ID: 21411717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity.
    Rasmussen N; Salmela A; Ekstrand A; de Groot K; Gregorini G; Cohen Tervaert JW; Gross WL; Wiik A; Jayne DR;
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S38-44. PubMed ID: 23380137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis.
    Dolman KM; Stegeman CA; van de Wiel BA; Hack CE; von dem Borne AE; Kallenberg CG; Goldschmeding R
    Clin Exp Immunol; 1993 Sep; 93(3):405-10. PubMed ID: 8370167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis.
    Rao JK; Allen NB; Feussner JR; Weinberger M
    Lancet; 1995 Oct; 346(8980):926-31. PubMed ID: 7564726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.
    Uysal P; Durmus S; Sozer V; Gelisgen R; Seyhan EC; Erdenen F; Simsek G; Uzun H
    Biomolecules; 2018 Aug; 8(3):. PubMed ID: 30154391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study.
    Girard T; Mahr A; Noël LH; Cordier JF; Lesavre P; André MH; Guillevin L
    Rheumatology (Oxford); 2001 Feb; 40(2):147-51. PubMed ID: 11257150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis.
    Kälsch AI; Csernok E; Münch D; Birck R; Yard BA; Gross W; Kälsch T; Schmitt WH
    J Rheumatol; 2010 Nov; 37(11):2319-25. PubMed ID: 20716656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.